Interestingly, the fusion of IFNα to anti-CD20 antibody induced a superior anti-lymphoma effect than anti-CD20 alone by direct and potent killing of type I IFNα receptor-positive lymphoma cells (68). This evidence concerns the gene IFNA1 and lymphoma.